Clinical trial
Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in…
NCT00004067 · NSABP Foundation Inc, Other · Completed
Key facts
| NCT number | NCT00004067 |
|---|---|
| Title | Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2 |
| Official title | A Randomized Trial Comparing the Safety and Efficacy of Adriamycin and Cyclophosphamide Followed by Taxol (AC-T) to That of Adriamycin and Cyclophosphamide Followed by Taxol Plus Herceptin (AC-T+H) in Node-Positive Breast Cancer Patients Who Have Tumors That Overexpress HER2 |
| Lead sponsor | NSABP Foundation Inc, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | herceptin, adriamycin, cyclophosphamide, taxol |
| Enrollment | 2,130 |
| Start date | Feb 1, 2000 |
| Primary completion | Mar 1, 2005 |
| Completion | Nov 1, 2019 |
| First posted | Jan 27, 2003 |
| Last update posted | Apr 29, 2021 |
| Countries | Canada, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: